Postmarketing hepatic adverse event experience with PEGylated/non-PEGylated drugs: A disproportionality analysis

European Journal of Gastroenterology and Hepatology

Volumn 19, Issue 11, 2007, Pages 934-941

  Hauben, Manfred ^a,b,c,e   Vegni, Ferdinando ^f   Reich, Lester ^a   Younus, Muhammad ^d  

^a PFIZER INC   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

^e BRUNEL UNIVERSITY   (United Kingdom)

^f PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Data mining; Hepatotoxicity; Non PEGylated drugs; PEGylated drugs; Pharmacovigilance

Indexed keywords

ALPHA FETOPROTEIN; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; ASPARAGINASE; BILIRUBIN; PEGASPARAGINASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ALGORITHM; ARTICLE; BILIARY TRACT DISEASE; CHOLANGITIS; DRUG FORMULATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FATTY LIVER; HEPATITIS; HEPATOMEGALY; HEPATOSPLENOMEGALY; HUMAN; JAUNDICE; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER FUNCTION; LIVER PAIN; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; PORPHYRIA; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; WORLD HEALTH ORGANIZATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ALGORITHMS; BIAS (EPIDEMIOLOGY); DATABASES, FACTUAL; DRUG CARRIERS; HUMANS; LIVER; POLYETHYLENE GLYCOLS; PRODUCT SURVEILLANCE, POSTMARKETING; WORLD HEALTH ORGANIZATION;

EID: 37349006881     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3282efa502     Document Type: Article

References (24)

1. Bush JK, Dai Wanju S, Dieck GS. The art and science of risk management: a US research-based industry perspective. Drug Saf 2005; 28:1-18.
2. Hamidi M, Azadi A, Rafiei P. Pharmacokinetic consequences of pegylation. Drug Deliv 2006; 13:399-409.
3. Crawford J. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. Semin Oncol 2003; 30:24-30.
4. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33:433-438.
5. Thigpen JT, Aghajanian CA, Alberts DS. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol 2005; 96:0-8.
6. Lorke J, Erhhardt A, Haussinger D. Induction of autoimmune hepatitis by pegylated interferon alfa-2b in chronic hepatitis C. Clin Gastroenterol Hepatol 2004; 2:xx.
7. Cholongitas E, Samonakis D, Patch D, Senzolo M, Burroughs AK, Quaglia A, et al. Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent hepatitis C virus. Transplantation 2006; 81:488-490.
8. James Matthews S, McCoy C. Peginterferon alfa-2a: a review of approved and investigational uses. Clin Ther 2004; 26:991-1025.
9. Jessner W, Kinaciyan T, Formann E, Steindl-Munda P, Ferenci P. Severe skin reactions during therapy for chronic hepatitis C associated with delayed hypersensitivity to pegylated interferons. Hepatology 2002; 36:361A. Abstract 793.
10. Abi-Nassif S, Mark EJ, Fogel RB, Hallisey RK Jr. Pegylated interferon and ribavirin-induced interstitial pneumonitis with ARDS. Chest 2003; 124:406-410.
11. Meller S, Erhardt A, Auci A. Drug-induced exanthema caused by pegylated IFN-alfa2b. Hautarzt 2003; 54:992-993.
12. Hauben M, Reich L, Gerrits CM, Younus M. Illusions of objectivity and a recommendation for reporting data mining results. Eur J Clin Pharmacol 2007; 63:517-521.
13. Hauben M, Madigan D, Gerrits CM, Walsh L, Van Puijenbroek EP. The role of data mining in pharmacovigilance. Expert Opin Drug Saf 2005; 4:929-948.
14. Noren NG, Bate A, Orr R, Edwards R. Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events. Stat Med 2006; 25:3740-3757.
15. Hauben M, Patadia VK, Goldsmith D. What counts in data mining? Drug Saf 2006; 29:827-832.
16. Zhao-Wong AC, Rump E, Moraleda T. Proposed terminology changes to facilitate the analysis of MedDRA-coded data. Drug Inform J 2006; 40:291-303.
17. Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001; 10:483-486.
18. Van Puijenbroek E, Diemont W, van Groothest K. Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions. Drug Saf 2003; 26:293-301.
19. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat 1999; 53:170-190.
20. Lindquist M, Stahl M, Bate A, Edwards IR, Meyboom RH. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf 2000; 23:533-542.
21. Bate A, Lindquist M, Edwards IR, Olsson S, Orre S, Lansner A, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998; 54:315-321.
22. Lanzante R. A cautionary note on the use of error bars. J Clim 2005; 18:3699-3703.
23. Hartnell NR, Wilson JP. Replication of the Weber effect using post-marketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy 2004; 24:743-749.
24. Aronson JK, Hauben M. Anecdotes that provide definitive evidence. BMJ 2006; 333:1267-1269.